Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339140 · ClinicalTrials.gov registry record · Phase 2
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04339140 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT04339140, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. * The name of the study drug involved in this study is: * Zafirlukast
Interventions
- DRUG Zafirlukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339140
The ClinicalTrials.gov registry entry for NCT04339140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zafirlukast is the first listed.
NCT04339140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04339140 about?
NCT04339140 is a clinical study titled "Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer". This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. * The name of the study drug involved in this study is: * Zafirlukast
What is the current status of trial NCT04339140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-06-24. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04339140?
The interventions under investigation include: Zafirlukast (DRUG).
Who is sponsoring clinical trial NCT04339140?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.